FRA

Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video

Retrieved on: 
Monday, February 12, 2024

Additionally, Optimi is pleased to unveil a six-minute video showcasing its end-to-end GMP MDMA encapsulation and production process.

Key Points: 
  • Additionally, Optimi is pleased to unveil a six-minute video showcasing its end-to-end GMP MDMA encapsulation and production process.
  • The FDA's priority review designation underscores the significance of this potential breakthrough in providing effective treatment options for those impacted by this debilitating condition.
  • Bill Ciprick, CEO of Optimi Health, stated, "We commend Lykos Therapeutics and MAPS founder, Rick Doblin, for their unwavering dedication to advancing innovative therapies for PTSD.
  • Stevens stated, "The ability to showcase our GMP MDMA production process is a testament to our commitment to excellence and transparency.

BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT

Retrieved on: 
Saturday, February 10, 2024

VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the final tranche of a non-brokered private placement (the "Private Placement") consisting of 16,716,666 ("Units") at a price of $0.03 per Unit for total gross proceeds of $501,500.

Key Points: 
  • VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the final tranche of a non-brokered private placement (the "Private Placement") consisting of 16,716,666 ("Units") at a price of $0.03 per Unit for total gross proceeds of $501,500.
  • Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant").
  • The Company intends to use the net proceeds of the Private Placement for working capital purposes.
  • The Company will pay a finder's fee of $16,976 in cash related to the final tranche of the financing.

BIOVAXYS ANNOUNCES COMPLETION OF FINAL TRANCHE OF PRIVATE PLACEMENT

Retrieved on: 
Saturday, February 10, 2024

VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the final tranche of a non-brokered private placement (the "Private Placement") consisting of 16,716,666 ("Units") at a price of $0.03 per Unit for total gross proceeds of $501,500.

Key Points: 
  • VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the final tranche of a non-brokered private placement (the "Private Placement") consisting of 16,716,666 ("Units") at a price of $0.03 per Unit for total gross proceeds of $501,500.
  • Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant").
  • The Company intends to use the net proceeds of the Private Placement for working capital purposes.
  • The Company will pay a finder's fee of $16,976 in cash related to the final tranche of the financing.

Refined Metals Corp. Announces Effective Date of Share Consolidation

Retrieved on: 
Saturday, February 10, 2024

VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Refined Metals Corp. (CSE: RMC; OTC: RFMCF; FRA:CWA0) (the “Company”) announces, further to its news release of January 26, 2024, that the consolidation of its issued and outstanding common shares on the basis of one post-consolidation common share (a “Post-Consolidation Share”) for every two currently-outstanding common shares (the “Consolidation”) will take place effective market open on February 15, 2024.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Refined Metals Corp. (CSE: RMC; OTC: RFMCF; FRA:CWA0) (the “Company”) announces, further to its news release of January 26, 2024, that the consolidation of its issued and outstanding common shares on the basis of one post-consolidation common share (a “Post-Consolidation Share”) for every two currently-outstanding common shares (the “Consolidation”) will take place effective market open on February 15, 2024.
  • On a pre-Consolidation basis, the Company has 57,288,955 issued and outstanding common shares and, following the Consolidation, the Company expects to have 28,644,478 Post-Consolidation Shares issued and outstanding.
  • If, as a result of the Consolidation, a shareholder would otherwise be entitled to a fraction of a Post-Consolidation Share, each fractional share following conversion that is at least one-half (1/2) of a Post-Consolidation Share will be rounded up to the nearest whole number and each fractional share that is less than one-half (1/2) of a Post-Consolidation Share will be cancelled.
  • The CUSIP number for its Post-Consolidation Shares will be 75867R203 and the ISIN for the Post-Consolidation Shares will be CA75867R2037.

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

Retrieved on: 
Saturday, February 10, 2024

VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500.

Key Points: 
  • VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500.
  • Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant").
  • The Company intends to use the net proceeds of the Private Placement for working capital purposes.
  • The Company anticipates closing the second and final tranche of the private placement no later than February 9th, 2024.

BIOVAXYS ANNOUNCES COMPLETION OF FIRST TRANCHE OF PRIVATE PLACEMENT

Retrieved on: 
Saturday, February 10, 2024

VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500.

Key Points: 
  • VANCOUVER, BC, Feb. 9, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it has completed the first tranche of a non-brokered private placement (the "Private Placement") consisting of 36,783,334 ("Units") at a price of $0.03 per Unit for total gross proceeds of $1,103,500.
  • Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant").
  • The Company intends to use the net proceeds of the Private Placement for working capital purposes.
  • The Company anticipates closing the second and final tranche of the private placement no later than February 9th, 2024.

Standard Lithium Spearheads Arkansas Lithium Innovation Summit

Retrieved on: 
Friday, February 9, 2024

LITTLE ROCK, Ark., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, is pleased to announce its presenting sponsorship of the Arkansas Lithium Innovation Summit, together with ExxonMobil, Albemarle, and TETRA Technologies.

Key Points: 
  • LITTLE ROCK, Ark., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, is pleased to announce its presenting sponsorship of the Arkansas Lithium Innovation Summit, together with ExxonMobil, Albemarle, and TETRA Technologies.
  • Scheduled for February 15-16, 2024, at the Robinson Center in Little Rock, the summit will bring together a cross-section of industry leaders, policymakers, and stakeholders.
  • Discussions will focus on Arkansas’s strategic contribution to the U.S. lithium supply chain through the high-grade Smackover brine resource and innovative direct lithium extraction technologies.
  • The summit will feature insightful keynotes from Arkansas Governor Sarah Huckabee Sanders, Secretary of Commerce Hugh McDonald, and U.S.

Looking Glass Labs Closes Definitive Agreement to Acquire Bot Media Corp.’s Climate and AI Web3 Assets

Retrieved on: 
Thursday, February 8, 2024

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Looking Glass Labs Ltd. ("LGL" or the "Company") (NEO: NFTX) (OTC: LGSLF) (FRA: H1N) is pleased to announce that further to the new release dated February 6, 2024 , it has closed the definitive agreement (the "Purchase Agreement"), to acquire the climate and artificial intelligence (AI) web3 assets (the "Purchased Assets") from Bot Media Corp. (the “Vendor”).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Looking Glass Labs Ltd. ("LGL" or the "Company") (NEO: NFTX) (OTC: LGSLF) (FRA: H1N) is pleased to announce that further to the new release dated February 6, 2024 , it has closed the definitive agreement (the "Purchase Agreement"), to acquire the climate and artificial intelligence (AI) web3 assets (the "Purchased Assets") from Bot Media Corp. (the “Vendor”).
  • Pursuant to the Purchase Agreement, the Company has issued an aggregate of 3,060,000 common shares at a deemed price of $0.25 per common share to the Vendor in full satisfaction of the purchase price of $765,000.
  • The securities issued pursuant to the Purchase Agreement have a statutory hold period in accordance with applicable securities laws which will expire on June 9, 2024.
  • No finder’s fees were paid on the Purchase Agreement.

Standard Lithium Reports Fiscal Second Quarter 2024 Results, Schedules Investor Update Call

Retrieved on: 
Thursday, February 8, 2024

VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today reported its financial and operating results for the fiscal second quarter ended December 31, 2023.

Key Points: 
  • VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today reported its financial and operating results for the fiscal second quarter ended December 31, 2023.
  • Salah Gamoudi, Chief Financial Officer of Standard Lithium added: “Despite a challenging commodity price environment, we expect to sustain our current operations through fiscal year 2024 with our cash available on-hand and the strategic use of our ATM program in place.
  • Subsequent to the fiscal second quarter-end, the Company selected Ausenco Engineering Canada ULC to lead the FEED and DFS studies for the project.
  • The Company will hold a conference call and webcast to discuss its second quarter fiscal results on Monday, February 12 at 11:00 a.m. EST.

Refined Metals Corp. Announces Change to Executive Management

Retrieved on: 
Thursday, February 8, 2024

In conjunction, Mr. Aman Parmar has stepped down as Interim Chief Executive Officer and remains a director of the Company.

Key Points: 
  • In conjunction, Mr. Aman Parmar has stepped down as Interim Chief Executive Officer and remains a director of the Company.
  • Mr. Fields has broad experience in overseeing mineral properties from exploration to production.
  • “On behalf of the Board of Directors, I would like to thank Aman for his service as the interim Chief Executive Officer of the Company,” said Mr. Fields.
  • As Chief Executive Officer of the Company, I am looking forward to growing the business of the Company in a manner that enhances our shareholders’ investment and grows shareholder value.”